Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of oridonin in preparation of anti-depression medicines

A technology of oridonin and anti-depression, which is applied in the direction of drug combination, pharmaceutical formula, medical preparations containing active ingredients, etc., to achieve the effect of ensuring reliability

Active Publication Date: 2016-10-26
罗永强
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, the use of oridonin as the active ingredient in the prevention / treatment of depression has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of oridonin in preparation of anti-depression medicines
  • Application of oridonin in preparation of anti-depression medicines
  • Application of oridonin in preparation of anti-depression medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1. Effect of Rubescensine A on Tail Suspension Experiment of Animal Depression Model

[0045] Experimental animals:

[0046] CD1 mouse, male, weighing 30-40 grams, provided by Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., license number: SCXK (Beijing) 2012-0001. The animals were reared in separate cages, with a light-dark cycle of 12h / 12h, room temperature 20-22°C, free access to water, and feed provided by the Experimental Animal Center of the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences.

[0047] Experimental Drugs:

[0048] Oridonin was purchased from China National Institutes for Food and Drug Control (Cat. No. 111721-201403).

[0049] Imipramine hydrochloride (Imipramine hydrochloride) is a product of Sigma Company, item number I7379, batch number O56K1380.

[0050] experiment equipment:

[0051] Cross bar; adhesive tape; Sumsung Intelli-200m digital video camera (Samsung Corporation of South Korea); JU...

Embodiment 2

[0068] Example 2. Effects of Rubescensine A on the Forced Swimming Test of Animal Depression Models

[0069] Experimental animals:

[0070] CD1 mice, male, were provided by Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., license number: SCXK (Beijing) 2012-0001. One week before the experiment, the animals were kept in separate cages, with a light-dark cycle of 12h / 12h, at a room temperature of 20-22°C, free access to water and food, and the feed was provided by the Experimental Animal Center of the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences.

[0071] Experimental drug:

[0072] Oridonin was purchased from China National Institutes for Food and Drug Control (Cat. No. 111721-201403).

[0073] The positive control imipramine hydrochloride (Imipramine hydrochloride) is a product of Sigma Company, product number I7379, lot number O56K1380.

[0074] laboratory apparatus:

[0075] Glass cylinder (height 40cm, diameter 14cm); mouse...

Embodiment 3

[0085] Embodiment 3. Mouse open-field experiment

[0086] Since the shortening of animal immobility time in the classic animal model of depression may be caused by the central excitatory effect of the drug, we conducted an open-field experiment in mice to examine the central excitatory effect of Rubescensin A.

[0087] The experimental results show that the total distance of the mice in the open box for 1 hour has no significant change (Anova, p>0.05, N=8-10), so the possibility of causing a manic state can be ruled out. Therefore, Rubescensin A does have a significant antidepressant effect.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technology of pharmacy, and particularly relates to application of oridonin in preparation of anti-depression medicines. The anti-depression medicinal ingredient of the anti-depression medicine provided by the invention is oridonin, and has an efficacy dosage 0.01-30mg oridonin per kilogram of the body weight; and an anti-depression effect can be generated in 60 minutes after the medicine is administrated. The medicine has the advantages of remarkable anti-depression effect, quick response, small dosage, small side effect and the like. In a mammal mouse tail suspension test, the oridonin has a more remarkable anti-depression effect than that of conventional anti-depression medicine imipramine, and is expected to become a novel quick and efficient anti-depression medicine without toxic or side effect.

Description

technical field [0001] The invention relates to pharmaceutical technology, in particular to the use of oridonin in the preparation of antidepressant drugs. Background technique [0002] Depression, also known as depressive disorder, is characterized by significant and persistent low mood as the main clinical feature. It can be seen clinically that the depression is not commensurate with the situation. The depression can range from depressed to distraught, low self-esteem and depression, even pessimistic and world-weary, and there may be suicide attempts or behaviors. Some cases have obvious anxiety and motor agitation, and in severe cases, hallucinations, delusions and other psychotic symptoms may appear. Each attack lasts for at least two weeks and lasts for several years. Most cases have a tendency to relapse, and most of each attack can be relieved, and some may have residual symptoms or become chronic. [0003] Medication is the main treatment for moderate to severe d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61P25/24
CPCA61K31/352
Inventor 杜若甫陈正华单丽萍
Owner 罗永强
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com